"Novo Nordisk's Multibillion-Dollar Expansion to Meet Weight-Loss Drug Demand"
Novo Nordisk has announced an $11 billion deal to expand its production of weight loss drugs, aiming to capitalize on the growing demand for treatments for obesity and related conditions. The Danish pharmaceutical company's investment will focus on increasing the capacity of its facilities in the US and Denmark, as it seeks to address the rising global prevalence of obesity and the need for effective medications.